Neumora Therapeutics (NMRA) Free Cash Flow (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Free Cash Flow of -$46.4 million for Q1 2026, up 21.94% year-over-year from -$38.1 million in Q1 2025, and up 3.23% quarter-over-quarter from -$48.0 million in Q4 2025.
Neumora Therapeutics (NMRA) Free Cash Flow (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Free Cash Flow history runs 5 years deep, the most recent figure standing at -$46.4 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 21.94% year-over-year to -$46.4 million; the TTM figure through Mar 2026 stood at -$193.4 million (up 3.03% YoY), while the FY2025 annual figure was -$206.4 million, down 12.85% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$46.4 million, up from -$48.0 million in the prior quarter.
- The five-year high for Free Cash Flow was -$30.9 million in Q4 2022, with the low at -$59.4 million in Q1 2025.
- The 5-year median for Free Cash Flow is -$47.2 million (2023), against an average of -$45.0 million.
- Peak annual rise in Free Cash Flow reached 29.97% in 2024, while the deepest fall reached 81.03% in 2024.
- Neumora Therapeutics' Free Cash Flow stood at -$30.9 million in 2022, then plunged by 66.89% to -$51.5 million in 2023, then rose by 2.23% to -$50.3 million in 2024, then gained by 4.74% to -$48.0 million in 2025, then grew by 3.23% to -$46.4 million in 2026.
- Business Quant data shows NMRA's Free Cash Flow at -$46.4 million in Q1 2026, -$48.0 million in Q4 2025, and -$46.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | -46.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.40 Mn |
| Mar 31, 2026 | -46.40 Mn |
| Dec 31, 2025 | -47.96 Mn |
| Dec 31, 2025 | -47.96 Mn |
| Sep 30, 2025 | -46.63 Mn |
| Sep 30, 2025 | -46.63 Mn |
| Jun 30, 2025 | -52.40 Mn |
| Jun 30, 2025 | -52.40 Mn |
| Mar 31, 2025 | -59.45 Mn |
| Mar 31, 2025 | -59.45 Mn |
| Dec 31, 2024 | -50.34 Mn |
| Dec 31, 2024 | -50.34 Mn |
| Sep 30, 2024 | -33.48 Mn |
| Sep 30, 2024 | -33.48 Mn |
| Jun 30, 2024 | -56.16 Mn |
| Jun 30, 2024 | -56.16 Mn |
| Mar 31, 2024 | -42.96 Mn |
| Mar 31, 2024 | -42.96 Mn |
| Dec 31, 2023 | -51.49 Mn |
| Dec 31, 2023 | -51.49 Mn |